التفاصيل البيبلوغرافية
| العنوان: |
Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial. |
| المؤلفون: |
Lim, Jae-Sung1 (AUTHOR), Lee, Juneyoung2 (AUTHOR), Kang, Yeonwook3 (AUTHOR), Park, Hyun-Tae4 (AUTHOR), Kim, Dong-Eog5 (AUTHOR), Cha, Jae-Kwan6 (AUTHOR), Park, Tai Hwan7 (AUTHOR), Heo, Jae-Hyuk7 (AUTHOR), Lee, Kyung Bok8 (AUTHOR), Park, Jong-Moo9 (AUTHOR), Oh, Mi Sun10 (AUTHOR), Kim, Eung-Gyu11 (AUTHOR), Chang, Dae-Il12 (AUTHOR), Heo, Sung Hyuk12 (AUTHOR), Park, Man-Seok13 (AUTHOR), Park, HyunYoung14 (AUTHOR), Yi, SangHak14 (AUTHOR), Lee, Yeong Bae15 (AUTHOR), Park, Kwang-Yeol16 (AUTHOR), Lee, Soo Joo17 (AUTHOR) |
| المصدر: |
Contemporary Clinical Trials. Mar2023, Vol. 126, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*COGNITION disorders, *PATIENT safety, *CLINICAL trials, *FUNCTIONAL magnetic resonance imaging, *MINI-Mental State Examination, *NEUROPSYCHOLOGY |
| مستخلص: |
Oxiracetam may have a modest effect on preventing cognitive decline. Exercise can also enhance cognitive function. This trial aims to investigate the effect of oxiracetam on post-stroke cognitive impairment and explore whether this effect is modified by exercise. Furthermore, the mechanisms that mediate this effect will be investigated through a neural network analysis. This is a multicenter, randomized, double-blind, placebo-controlled phase IV trial. Patients who complained of cognitive decline 3 months after stroke and had a high risk of cognitive decline were eligible. Patients were randomly assigned to receive either 800 mg of oxiracetam or placebo twice daily for 36 weeks. After randomization, a predetermined exercise protocol was provided to each participant, and the degree of physical activity was assessed using wrist actigraphy at 4, 12, 24, and 36 weeks. Resting-state functional MRI was obtained in baseline and 36-week follow-up. Co-primary endpoints are changes in the Mini-Mental State Examination and Clinical Dementia Rating-Sum of Boxes. Secondary endpoints include changes in the NINDS-CSN VCIHS-Neuropsychology Protocol, Euro QoL, patient's global assessment, and functional network connectivity. If there is a significant difference in physical activity between the two groups, the interaction effect between physical activity and the treatment group will be examined. A total of 500 patients were enrolled from February 2018, and the last patient's final follow-up was completed in September 2022. This trial is meaningful not only to prove the efficacy of oxiracetam, but also evaluate whether exercise can modify the effects of medication and how cognitive function can be restored. Trial registration http://cris.nih.go.krTest (KCT0005137). [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
